The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism

Abstract

The use of radioactive iodine in the treatment of hyperthyroidism is common practice. However, a standardized treatment protocol with regard to radioactive iodine treatment (RAI) remains subject to discussion. We retrospectively analyzed 100 patient records. Patient diagnosis, age, gender, body mass index (BMI), dose of radioactive iodine, thyroid size, the 24 h radioiodine uptake (24 h RAIU) and protein bound iodine (PBI) were deducted, as well as the use of antithyroid drugs prior to RAI. Biochemical parameters were obtained, such as TSH, fT4, fT3, Anti-TPO, Anti-TG antibodies and thyroid stimulating antibodies. After 5 years of follow-up, 46% of the patients proved to be hypothyroid, whereas 8% of the patients were not cured after one dose of RAI. One year after RAI, a larger proportion of patients with a toxic nodule developed hypothyroidism compared to patients with a multinodular goiter (MNG) (44.2% vs. 21.2%). Radioactive iodine dose, PBI, RAIU, BMI, size of the thyroid gland, diagnosis, age and TPO-antibodies showed statistically significant differences in the development of hypothyroidism. Furthermore, thiamazole pretherapy was shown to be a predictor of hypothyroidism, as well as a high PBI value, exhibiting a positive predictive value of 85.2% when the PBI exceeded 0.16. We suggest a standardized measurement of TPO-Ab’s to further determine their role in the development of hypothyroidism after RAI. The empirical dosing regimen was very effective, illustrating a 92% cure rate after 1 dose.

Key words

radioactive iodine - hypothyroidism - protein bound iodine - TPO-antibodies

Publikationsverlauf

Eingereicht: 02. April 2022

Angenommen nach Revision: 06. November 2023

Accepted Manuscript online:
06. November 2023

Artikel online veröffentlicht:
19. Dezember 2023

• References

• 1 Taylor PN, Albrecht D, Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018; 14: 301-316
• 2 Onimode YA, Dairo DM, Ellmann A. Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men. Pan Afr Med J 2018; 29: 48
• 3 Łacka K, Fraczek MM. Classification and etiology of hyperthyroidism. Pol Merkur Lekarski 2014; 36: 206-211
• 4 de Jong JA, Verkooijen HM, Valk GD. et al. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med 2013; 38: 401-406
• 5 Ross DS, Burch HB, Cooper DS. et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421
• 6 Freitas JE. Therapeutic options in the management of toxic and nontoxic nodular goiter. Semin Nucl Med 2000; 30: 88-97
• 7 Graf H. Recombinant human TSH and radioactive iodine therapy in the management of benign multinodular goiter. Eur J Endocrinol 2015; 172: R47-R52
• 8 Nygaard B, Hegedüs L, Gervil M. et al. Radioiodine treatment of multinodular non-toxic goitre. BMJ 1993; 307: 828-832
• 9 Reid JR, Wheeler SF. Hyperthyroidism: diagnosis and treatment. Am Fam Physician 2005; 72: 623-630
• 10 Canto AU, Dominguez PN, Jimeno CA. et al. Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves disease in adults. Endocrinol Metab (Seoul) 2016; 31: 168-173
• 11 Beslic N, Licina S, Sadija A. et al. Incidence of hypothyreoidism after radioactive iodine-I131 treatment in dependance of hyperthyreoidism etiology and therapy dose. Med Arch 2017; 71: 270-273
• 12 Tuttle RM, Leboeuf R, Robbins RJ. et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006; 47: 1587-1591
• 13 Green M, Wilson GM. Thyrotoxicosis treated by surgery or iodine-131. With special reference to development of hypothyroidism. Br Med J 1964; 1: 1005-1010
• 14 Vandevijvere S, Ruttens A, Wilmet A. et al. Urinary sodium and iodine concentrations among Belgian adults: results from the first national Health Examination Survey. Eur J Clin Nutr 2021; 75: 689-696
• 15 Ahmad AM, Ahmad M, Young ET. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. Eur J Endocrinol 2002; 146: 767-775
• 16 Dong Q, Liu X, Wang F. et al. Dynamic changes of TRAb and TPOAb after radioiodine therapy in Graves' disease. Acta Endocrinol (Buchar) 2017; 13: 72-76
• 17 Wan Mohamed WMI, Sayuti SC, Draman N. Hypothyroidism and its associated factors after radioactive iodine therapy among patients with hyperthyroidism in the Northeast Coast State of Malaysia. J Taibah Univ Med Sci 2018; 13: 432-437
• 18 Mahmud MK, Jalil S, Rahman AM. et al. Etiologies and posttreatment conditions of thyrotoxic patients in Sylhet division, Bangladesh: a clinical series. Avicenna J Med 2017; 7: 125-129
• 19 Kyrilli A, Tang BN, Huyge V. et al. Thiamazole pretreatment lowers the (131)I activity needed to cure hyperthyroidism in patients with nodular goiter. J Clin Endocrinol Metab 2015; 100: 2261-2267
• 20 Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86: 3488-3493
• 21 Karyampudi A, Hamide A, Halanaik D. et al. Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole therapy. Indian J Endocrinol Metab 2014; 18: 688-693
• 22 Aktay R, Rezai K, Seabold JE. et al. Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism. J Nucl Med 1996; 37: 1815-1819
• 23 Bhat M, Mozzor M, Chugh S. et al. Dosing of radioactive iodine in end-stage renal disease patient with thyroid cancer. Endocrinol Diabetes Metab Case Rep 2017; 17-0111
• 24 Moslehi M, Mahmoud-Pashazadeh A, Tahmasebi R. et al. Effect of administrated activity, admission number and TSH level on radiation retention curve of patients taking iodine-131 therapy for differentiated thyroid carcinoma: Looking beyond established regulations. Iran J Nucl Med 2018; 47-53